Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCH346 Safety and Dose-ranging Study in ALS
NCT00036413Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2002
- Primary completion
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omigapil in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Novartis. Primary endpoint: Safety of three oral doses of TCH346 versus placebo at 12 weeks. Started Jan 2002; status: completed.
02
Drugs
omigapil
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00036413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036413.